In this edition of Quick Notes, we review recent FDA drug approvals of Zepbound for weight loss, Fruzaqla for colorectal cancer, Cosentyx for hidradenitis suppurativa, Keytruda for biliary cancer, and Stelara biosimilar Wezlana for several inflammatory diseases.
Source: Drug Industry Daily